Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 8/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500376 | 0.91 | CKS1B (0.43) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL21810255 | 0.89 | CKS1B (0.42) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL20500354 | 0.89 | CKS1B (0.42) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL20500366 | 0.89 | CKS1B (0.42) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL20500364 | 0.88 | CKS1B (0.41) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL21810209 | 0.88 | CKS1B (0.41) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL20500372 | 0.86 | CKS1B (0.40) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL20500391 | 0.82 | CKS1B (0.41) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL23658238 | 0.81 | CKS1B (0.43) | SSTR2CKS1BSKP1SKP2SYK | |
| SCHEMBL30897156 | 0.81 | SSTR2 (0.44) | SSTR2CKS1BSKP1SKP2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110650951-B | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-11072598-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-27 | — | — | US | disclosed |
| CN-110650951-A | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2020-01-03 | — | — | CN | disclosed |
| WO-2018170284-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072598-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | SSTR2 2/4885CKS1B 3617/4885SKP1 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.